13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | -$194M | 0.0% | -94.6% | -$126M | — | $34M |
| 2024 | $83M | -$227M | 59.7% | -280.0% | -$176M | — | $58M |
| 2023 | $90M | -$263M | 58.8% | -297.1% | -$228M | — | $35M |
| 2022 | $113M | -$280M | 51.6% | -233.2% | -$238M | — | $97M |
| 2021 | $470M | $128M | 89.0% | 34.0% | $135M | — | $345M |
| 2020 | $155M | -$111M | 76.9% | -77.1% | -$81M | — | $338M |
| 2019 | $35M | -$95M | 76.6% | -422.9% | -$119M | — | $70M |
| 2018 | $219M | $100M | 95.6% | 40.3% | $91M | — | $76M |
| 2017 | $10M | -$73M | 83.6% | -730.2% | -$65M | — | $47M |
| 2016 | $5M | -$63M | 0.0% | -1423.8% | -$57M | — | $25M |
| 2015 | — | -$23M | — | — | — | — | $54M |
| 2014 | — | -$4M | — | — | — | — | $1M |
| 2013 | — | -$5M | — | — | — | — | $1M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $6M | -$90M | 0.0% | -1304.0% | -$77M | — | $15M |
| Dec '25 | $30M | -$67M | 0.0% | -190.0% | -$53M | — | $34M |
| Sep '25 | $30M | -$62M | 0.0% | -176.3% | -$56M | — | $59M |
| Jun '25 | $21M | -$71M | 0.0% | -296.3% | -$50M | — | $80M |
| Mar '25 | $89M | $6M | 0.0% | 13.6% | $33M | — | $130M |
| Dec '24 | $21M | -$51M | 70.2% | -242.1% | -$33M | — | $58M |
| Sep '24 | $24M | -$60M | 48.8% | -256.6% | -$41M | — | $57M |
| Jun '24 | $22M | -$53M | 52.5% | -251.3% | -$46M | — | $58M |
| Mar '24 | $16M | -$63M | 72.6% | -408.8% | -$56M | — | $113M |
| Dec '23 | $22M | -$63M | 49.4% | -287.7% | -$42M | — | $35M |
| Sep '23 | $29M | -$62M | 57.2% | -224.7% | -$51M | — | $53M |
| Jun '23 | $20M | -$72M | 52.6% | -366.0% | -$50M | — | $69M |
| Mar '23 | $19M | -$67M | 78.5% | -345.7% | -$86M | — | $70M |
| Dec '22 | $31M | -$60M | 59.2% | -184.3% | -$45M | — | $97M |
| Sep '22 | $27M | -$75M | 50.6% | -268.0% | -$56M | — | $119M |
| Jun '22 | $33M | -$68M | 60.3% | -191.5% | -$71M | — | $121M |
| Mar '22 | $22M | -$77M | 29.3% | -321.9% | -$67M | — | $192M |
| Dec '21 | $399M | $294M | 94.2% | 78.7% | $327M | — | $345M |
| Sep '21 | $31M | -$58M | 54.2% | -186.4% | -$61M | — | $228M |
| Jun '21 | $22M | -$58M | 55.4% | -237.0% | -$56M | — | $257M |
How the market has priced RGNX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Regenxbio Inc.'s revenue has grown 2.0% per year. These are computed facts, not advice.
As of FY2025, Regenxbio Inc. reported — of total debt against $34M of cash; operating income covered interest expense -3.6×.
In FY2025, gross margin was —, operating margin -94.6%, and net margin -113.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.